- Home
- BIRD vs IGC Comparison
BIRD vs IGC Comparison
Compare BIRD & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIRD | IGC |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 25.0M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BIRD | IGC |
|---|---|---|
| Price | $2.69 | $0.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.00 | $5.00 |
| AVG Volume (30 Days) | 138.1K | ★ 225.9K |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.22 | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,466,000.00 | $1,271,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | $30.99 | $15.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.15 | $0.24 |
| 52 Week High | $12.84 | $0.50 |
Technical Indicators
Market Signals| Indicator | BIRD | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 46.35 |
| Support Level | $2.45 | $0.25 |
| Resistance Level | $3.48 | $0.31 |
| Average True Range (ATR) | 0.30 | 0.02 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 35.42 | 30.20 |
Price Performance
Historical ComparisonAbout BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.